Gilead Sciences (GILD) saw its stock plummet 5.02% in intraday trading on Tuesday, as President Donald Trump signaled he would make an announcement next week on the cost of medicines. The biotech giant's shares fell alongside other major drugmakers amid renewed concerns about potential pharmaceutical tariffs and pricing pressures.
Trump told reporters at the White House that the U.S. was being "ripped off on medicine costs" compared to the rest of the world. He also mentioned plans to announce pharmaceutical tariffs over the next two weeks, raising investor anxiety about the potential impact on drug companies' profits.
The news sent shockwaves through the healthcare sector, with the S&P 500 healthcare index falling 1.5%. Other major pharmaceutical companies also saw significant declines, with Eli Lilly and AbbVie down 3% each, Merck falling 2.5%, and Amgen dropping 2.2%.
While the specific details of Trump's upcoming announcement remain unclear, the market reaction reflects ongoing concerns about potential government intervention in drug pricing. Investors will be closely watching for further developments, as any significant changes to pricing policies could have far-reaching implications for Gilead Sciences and the broader pharmaceutical industry.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。